Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan-Dec:13:21501319221138196.
doi: 10.1177/21501319221138196.

Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes

Affiliations

Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes

Joji Tokita et al. J Prim Care Community Health. 2022 Jan-Dec.

Abstract

Introduction and objective: The lack of precision to identify patients with early-stage diabetic kidney disease (DKD) at near-term risk for progressive decline in kidney function results in poor disease management often leading to kidney failure requiring unplanned dialysis. The KidneyIntelX is a multiplex, bioprognostic, immunoassay consisting of 3 plasma biomarkers and clinical variables that uses machine learning to generate a risk score for progressive decline in kidney function over 5-year in adults with early-stage DKD. Our objective was to assess the impact of KidneyIntelX on management and outcomes in a Health System in the real-world evidence (RWE) study.

Methods: KidneyIntelX was introduced into a large metropolitan Health System via a population health-defined approved care pathway for patients with stages 1 to 3 DKD between [November 2020 to March 2022]. Decision impact on visit frequency, medication management, specialist referral, and selected lab values was assessed. We performed an interim analysis in patients through 6-months post-test date to evaluate the impact of risk level with clinical decision-making and outcomes.

Results: A total of 1686 patients were enrolled in the RWE study and underwent KidneyIntelX testing and subsequent care pathway management. The median age was 68 years, 52% were female, 26% self-identified as Black, and 94% had hypertension. The median baseline eGFR was 59 ml/minute/1.73 m2, urine albumin-creatinine ratio was 69 mg/g, and HbA1c was 7.7%. After testing, a clinical encounter in the first month occurred in 13%, 43%, and 53% of low-risk, intermediate-risk, and high-risk patients, respectively and 46%, 61%, and 71% had at least 1 action taken within the first 6 months. High-risk patients were more likely to be placed on SGLT2 inhibitors (OR = 4.56; 95% CI 3.00-6.91 vs low-risk), and more likely to be referred to a specialist such as a nephrologist, endocrinologist, or dietician (OR = 2.49; 95% CI 1.53-4.01) compared to low-risk patients.

Conclusions: The combination of KidneyIntelX, clinical guidelines and educational support resulted in changes in clinical management by clinicians. After testing, there was an increase in visit frequency, referrals for disease management, and introduction to guideline-recommended medications. These differed by risk category, indicating an impact of KidneyIntelX risk stratification on clinical care.

Keywords: KidneyIntelX; Real World Evidence; decision impact study; diabetic kidney disease; early-stage.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AZ, FL, and MJD are employees of Renalytix; SC and GN are consultants for Renalytix.

Figures

Figure 1.
Figure 1.
RWE clinical study diagram.
Figure 2.
Figure 2.
KidneyIntelX contains a risk score and categorization linked to a guideline driven care path.
Figure 3.
Figure 3.
Time to specialist referral. Time to specialist referral based on (a) KidneyIntelX and (b) Sankey Flow diagram demonstrating proportion of referrals based on provider. Greater than 20% increase in referrals for patients at high- versus low-risk for progression of their DKD ordered by their Primary Care Physician (high-risk vs low-risk, new referrals; OR = 2.49; 95% CI: 1.53-4.01).
Figure 4.
Figure 4.
Decision impact of KidneyIntelX risk level on new prescriptions for SGLT2 inhibitors. (a) Post-test result at 6 months in the high- (25%) vs low-risk (7%) groups (OR = 4.56; 95% CI: 3.00-6.91) and (b) the physician type most likely to order SGLT2 inhibitors.

References

    1. USRDS. Annual data report. Accessed August 22, 2022. https://www.usrds.org/annual-data-report/
    1. Official Journal of the international Society of nephrology KDIGO 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Accessed August 22, 2022. www.publicationethics.org - PubMed
    1. Dunkler D, Gao P, Lee SF, et al. Risk prediction for early CKD in type 2 diabetes. Clin J Am Soc Nephrol. 2015;10(8):1371-1379. doi: 10.2215/CJN.10321014 - DOI - PMC - PubMed
    1. Sprangers B, Evenepoel P, Vanrenterghem Y. Late referral of patients with chronic kidney disease: no time to waste. Mayo Clin Proc. 2006;81(11):1487-1494. - PubMed
    1. Kagoma YK, Weir MA, Iansavichus AV, et al. Impact of estimated GFR reporting on patients, clinicians, and health-care systems: a systematic review. Am J Kidney Dis. 2011;57(4):592-601. - PubMed

Substances

LinkOut - more resources